This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Gambles on Building an Alzheimer's Empire

Updated from 2:39 p.m. EST

With Monday's $68 billion bid to acquire Wyeth (WYE), pharmaceutical giant Pfizer (PFE - Get Report) is setting itself up to potentially dominate the Alzheimer's disease treatment market for years to come. But in making such a big bet on one of society's most pressing unmet medical needs, the pharmaceutical giant may also face increased government scrutiny and possibly some resistance from its key partners.

Pfizer and the Japanese drug maker Eisai, currently co-market Aricept, the leading Alzheimer's drug today with worldwide sales of more than $2 billion.

But Aricept loses patent protection at the end of next year, which is one reason why Pfizer has decided to invest heavily in new Alzheimer's drug research.

Stock Rating
Thomas P. Au:
The deal makes sense.

Last September, Pfizer acquired worldwide commercial rights to Dimebon, an experimental Alzheimer's drug currently in phase III studies. Pfizer paid Medivation (MDVN - Get Report), Dimebon's owner, $225 million upfront for the rights, making it one of the largest drug partnership deals of 2008.

Pfizer also has four Alzheimer's drugs in its own pipeline, most of which are in the early stages of clinical trials. This includes an experimental Alzheimer's drug acquired in 2006 when Pfizer bought privately held Rinat Neuroscience.

Wyeth has 10 Alzheimer's drugs in clinical trials, both internally and through partnerships, the most important of which is with Irish drug maker Elan (ELN). The two companies share development efforts and marketing rights to bapineuzumab, which is being studied in four phase III clinical trials.

If the acquisition of Wyeth announced Monday closes as is, Pfizer would boost its Alzheimer's drug pipeline from five drugs in clinical trials to 15, including two of the four drugs currently in pivotal phase III studies. ( Eli Lilly (LLY - Get Report) and Baxter (BAX - Get Report) own the other two phase III Alzheimer's drugs.)
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
BAX $37.68 0.00%
LLY $83.65 0.00%
MDVN $41.68 0.00%
PFE $32.79 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs